Opinion: From Data Silos Still Slow Pharmaceutical Logistics
Updated: 16 hours ago
The pharmaceutical supply chain has become increasingly sophisticated. Advanced biologics, cell and gene therapies, vaccines, and personalized medicines now move through global logistics networks involving manufacturers, logistics providers, airlines, ground handlers, customs authorities, distribution centers, and healthcare providers. Yet despite major investments in cold chain infrastructure and monitoring technologies, one fundamental challenge remains: logistics data is still fragmented across multiple stakeholders and systems.
As Vice President of PharmacomItalia, I believe that building greater trust and transparency across the pharmaceutical supply chain will be one of the industry's key priorities in the coming years. By combining digital innovation, real-time visibility, and collaboration among all stakeholders, we can strengthen supply chain resilience and ensure the integrity of pharmaceutical products from origin to destination.
Today, the industry generates vast amounts of valuable operational data. Temperature sensors, GPS tracking systems, freight management platforms, quality databases, and logistics providers all collect information that can contribute to product integrity and supply chain performance. However, this information often remains locked within individual organizations, stored in different formats, and disconnected from other critical events occurring throughout the transportation journey.
Before medicines can be released for distribution or patient use, manufacturers must verify that transportation conditions remained within validated parameters. Quality teams frequently spend considerable time collecting temperature records, transportation milestones, handling information, and quality documents from multiple parties before making a release decision. When a deviation or temperature excursion occurs, investigations often become lengthy exercises involving emails, spreadsheets, reports, and data from several organizations. The issue is not the lack of information. The issue is the lack of connectivity.
Visibility Must Lead to Actionable Intelligence
Over the last decade, the industry has focused primarily on visibility. We can increasingly see where shipments are and what temperatures they experience during transport. However, visibility alone is not enough. What the pharmaceutical sector truly needs is the ability to connect data across organizational boundaries and transform isolated information into actionable intelligence.
At PharmacomItalia, we believe that the future of pharmaceutical logistics depends on the creation of trusted data ecosystems that bring together manufacturers, logistics providers, and technology partners. For this reason, we are launching a series of collaborative projects in 2027 involving pharmaceutical companies, logistics organizations, and key industry stakeholders. The objective is to demonstrate that secure logistics data sharing is possible and can create measurable value for participants.
Connect Existing Systems Through Trusted Data Sharing
These initiatives will explore how operational milestones, environmental monitoring data, quality records, and transportation events can be connected across the supply chain while respecting each participant's ownership and governance of their data. Rather than asking organizations to replace existing systems, the focus is on enabling interoperability and creating a common framework for trusted information exchange.
One of the enabling technologies supporting these projects is OMNIA, a platform designed to connect logistics and quality data from multiple sources into a unified ecosystem. Its role within these initiatives is to help demonstrate how data can be aggregated, contextualized, and shared across different stakeholders in a practical and scalable way.
Build a Connected Data Chain
Connected data ecosystems can accelerate product release processes, shorten deviation investigations, improve audit readiness, reduce administrative burdens, and provide greater confidence in product integrity throughout the supply chain. Most importantly, they can help ensure that critical medicines reach patients faster and with higher levels of assurance.
The pharmaceutical industry has successfully built a highly connected physical cold chain. The next challenge is building an equally connected data chain.
As we move into 2027, collaboration will be key to unlocking this opportunity. By working together across the pharmaceutical and logistics sectors, we can demonstrate that data sharing can be secure, practical, and beneficial for all stakeholders. The future will belong to those who can transform fragmented information into shared intelligence that enables faster, better, and more confident decisions.
By Marco Del Giudice, Vice President of PharmacomItalia. The views expressed are the author’s own. References to PharmacomItalia’s projects and the OMNIA platform reflect the author’s perspective and do not constitute an endorsement by The Supply Chainer.
